Posts

Eli Lilly sues six companies over alleged illegal sales of retatrutide knockoffs

Eli Lilly (Lilly) has filed six lawsuits against U.S. companies accused of illegally selling knockoff or black-market versions of its experimental obesity and weight-loss drug retatrutide. The defendants include Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide — ranging from online peptide sellers and compounding pharmacies to medical spas. Lilly alleges these firms are marketing purported retatrutide as "for research use only" while effectively selling it for human injection, bypassing FDA oversight and patient safeguards. Retatrutide is still in clinical trials and has not been approved by the FDA or any other regulator; Lilly argues unapproved knockoffs endanger consumers with unverified, potentially contaminated products and damage the drug’s future reputation. The lawsuits are part of a broader crackdown in which Lilly has referred over 200 other entities to U.S. authorities and reported more than 14,000 ...

Definium Hits Another Phase 3 Homerun with Psychedelic Sea Change for Anxiety

Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset alvelestat for AATD-LD

From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing – Recent industry trends and challenges

FDA panel to review Grail's blood‑based multi‑cancer early detection test

Trump signs executive order to overhaul pediatric vaccine recommendations

Epicrispr secures $90M after early data on epigenetic FSHD treatment | 2026-08-11

AbbVie, Novartis and Bristol Myers Squibb Sue Illinois Over 340B Contract Pharmacy Law

Lilly's $3.8B vaccine biotech spree and Infinimmune's $75M raise

Ying Huang's post-Legend Life Takes Shape at K2 With $250M Goal to License Asia Assets

Rare Disease Drugmakers Watch FDA for Renewed Focus on Therapies

Phase II win for Silence's divesiran in PV lifts bar for Takeda's rusfertide

Trump signs executive order to overhaul pediatric vaccine recommendations – August 2026